This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles G. Moertel, MD

JAMA. 1986;256(22):3141.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Advanced cancer will take the lives of almost half a million Americans this year. Certainly, any claim of therapeutic accomplishment in this area will attract major public interest. In recent times, this interest has been focused on the lymphokines and cytokines, natural substances that man produces as a defense against the diseases that may afflict him. Through ingenious recombinant DNA technologies, these substances can be produced in quantities sufficiently large to permit therapeutic application. Numbered among these are the interferons, tumor necrosis factor, and the interleukins.

In this issue of THE JOURNAL, a group of investigators present a second report¹ of their work with high doses of interleukin 2 (IL-2) used either alone or, as first reported,² in combination with lymphokine-activated killer (LAK) cells. Following their first publication, these authors described their work as a "breakthrough"; since this claim bore the imprimatur of the National Cancer Institute, it . . . [Full Text PDF of this Article]

Author Affiliations
Mayo Clinic Rochester, Minn

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?